<DOC>
	<DOCNO>NCT01721590</DOCNO>
	<brief_summary>Tongxinluo kind Chinese patent drug , could promote blood circulation.Recent report suggest tongxinluo 's effectiveness reduce thrombin activity.In prospective randomize study , patient control group receive blank placebo , patient test group receive tongxinluo.All patient follow one year .</brief_summary>
	<brief_title>Tongxinluo Improve High Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease</brief_title>
	<detailed_description>The primary endpoint Platelet Reaction Unit ( VerifyNow ) 30 days.The secondary endpoint include inflammation marker ( hsCRP、CD62P-CD41 ) , TT , FIB PT 30 day , MI、Ischemic Stroke , target vessel revascularization all-cause mortality 、bleeding event 1 year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>( 1 ) ACS ( include unstable angina pectoris , nonSTsegment elevation myocardial infarction STelevation myocardial infarction ) （2）Accept least one coronary stent . （3）The age between18 75 . （4）High ontreatment platelet reactivity define ADPinduced platelet aggregation ( VerifyNow，PRU≥236）at 24 hr clopidogrel loading ( 300 ~ 600mg ) 24 hour PCI . （5）Informed Consent （1）Tongxinluo contraindication . （2）Receiving GP IIb / IIIa receptor antagonist treatment （3）Who complicate know bleeding tendency blood system diseases . （4）NYHA grade III ~ IV （5）Aspirin clopidogrel allergy （6）Severe liver kidney dysfunction （7）Pregnancy （8）Can n't accept 30 day supervision blood proofer . （9）Other serious illness , life expectancy le 6 month . （10 ) Planned surgery recently （11 ) PCI within 30 day . ( 12 ) Mental diseases interfere understand informed consent form （13）Accept drug participate clinical research time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>high on-treatment platelet reactivity</keyword>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>Tongxinluo</keyword>
</DOC>